Stanozolol

ID: stanozolol

Aliases: Winstrol, Winny

Type: compound

Route/form: oral or intramuscular depending product/history

Status: legacy_or_discontinued_human_use

Evidence level: early human

Best data tier: early human + case-report/safety

Support scope: human, review/regulatory

Source types: case_report, human_trial, review, safety_review

Linked sources: 7

Broad outcomes: Fat loss / metabolic health, Gut / immune / inflammation, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor agonist
• 17-alpha-alkylated AAS
• C1 esterase inhibitor increase in hereditary angioedema context

Optimization domains

• steroid
• muscle
• body composition
• hereditary angioedema
• doping
• liver

Research basis

• Human hereditary-angioedema literature anchors legitimate historical clinical use separate from physique claims.
• It is a common oral/injectable AAS in PED discussions and should be represented with hepatic, lipid, and androgen-risk context.
• The HAE sources show attenuated-androgen efficacy at low clinical doses, which is a very different claim from high-dose performance use.

Limits, risks, and missing evidence

• Clinical HAE use does not establish safe nonmedical use, and oral AAS hepatic/lipid risks remain important.
• Stanozolol is not joint-protective just because users describe a dry look; tendon, lipid, liver, and suppression risks still dominate.
• Long-term attenuated-androgen reviews in HAE are cautionary for monitoring burden, not an endorsement of casual PED use.

Risk flags

• oral 17aa aas
• hepatic risk
• lipid risk
• endocrine suppression
• doping

Linked papers, labels, and reviews

1. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema
   human_trial / pubmed_stanozolol_hae_1981
   Clinical hereditary-angioedema source for stanozolol; indication-specific and not physique evidence.
2. Acute liver failure associated with anabolic-androgenic steroid use
   case_report / pubmed_stanozolol_liver_failure_2014
   Safety signal source involving anabolic steroid misuse; useful for hepatic-risk framing around stanozolol and oral AAS.
3. Anabolic androgenic steroid-induced liver injury: an update
   safety_review / pubmed_aas_liver_effects_2018
   Class hepatic-risk review, especially relevant for 17-alpha-alkylated oral AAS such as oxymetholone, methandienone, stanozolol, and oxandrolone.
4. Anabolic-androgenic steroids: How do they work and what are the risks?
   review / pubmed_aas_risks_2023
   General AAS mechanism and risk review; used as class-level caution for nonmedical androgen/anabolic steroid entries.
5. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema
   human_trial / pubmed_stanozolol_hae_danazol_1980
   Older HAE prophylaxis source comparing attenuated androgens; clinical route/context differs from PED use.
6. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
   review / pubmed_attenuated_androgens_hae_review_2022
   Review of attenuated androgen prophylaxis in HAE; useful for stanozolol/danazol benefit-risk context and long-term adverse effects.
7. Anabolic-androgenic steroids among recreational athletes and cardiovascular risk
   safety_review / pubmed_aas_recreational_athletes_cv_review_2025
   Recent cardiovascular-risk review focused on recreational athlete AAS use; class-level safety source for nonmedical androgen entries.